KR20150013629A - 노화 관련 질환에 대처하기 위한 shc-1/p66 억제 방법 - Google Patents

노화 관련 질환에 대처하기 위한 shc-1/p66 억제 방법 Download PDF

Info

Publication number
KR20150013629A
KR20150013629A KR1020147033339A KR20147033339A KR20150013629A KR 20150013629 A KR20150013629 A KR 20150013629A KR 1020147033339 A KR1020147033339 A KR 1020147033339A KR 20147033339 A KR20147033339 A KR 20147033339A KR 20150013629 A KR20150013629 A KR 20150013629A
Authority
KR
South Korea
Prior art keywords
shc
formula
acyl
composition
independently hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147033339A
Other languages
English (en)
Korean (ko)
Inventor
창샤우펑
마춘씨엔
양쿠오위
Original Assignee
재단법인 공업기술연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 재단법인 공업기술연구원 filed Critical 재단법인 공업기술연구원
Publication of KR20150013629A publication Critical patent/KR20150013629A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/30—Fuel from waste, e.g. synthetic alcohol or diesel

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020147033339A 2012-12-26 2013-05-14 노화 관련 질환에 대처하기 위한 shc-1/p66 억제 방법 Ceased KR20150013629A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/727,387 US20140179774A1 (en) 2012-12-26 2012-12-26 Methods for inhibition of shc-1/p66 to combat aging-related diseases
US13/727,387 2012-12-26
PCT/CN2013/075599 WO2014101366A1 (en) 2012-12-26 2013-05-14 Methods for inhibition of shc-1/p66 to combat aging-related diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177005294A Division KR20170027860A (ko) 2012-12-26 2013-05-14 노화 관련 질환에 대처하기 위한 shc-1/p66 억제 방법

Publications (1)

Publication Number Publication Date
KR20150013629A true KR20150013629A (ko) 2015-02-05

Family

ID=50975338

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020147033339A Ceased KR20150013629A (ko) 2012-12-26 2013-05-14 노화 관련 질환에 대처하기 위한 shc-1/p66 억제 방법
KR1020177005294A Ceased KR20170027860A (ko) 2012-12-26 2013-05-14 노화 관련 질환에 대처하기 위한 shc-1/p66 억제 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177005294A Ceased KR20170027860A (ko) 2012-12-26 2013-05-14 노화 관련 질환에 대처하기 위한 shc-1/p66 억제 방법

Country Status (8)

Country Link
US (1) US20140179774A1 (enExample)
EP (1) EP2838528B1 (enExample)
JP (1) JP6305422B2 (enExample)
KR (2) KR20150013629A (enExample)
CN (1) CN104487069A (enExample)
IN (1) IN2014MN02382A (enExample)
SG (1) SG11201407425SA (enExample)
WO (1) WO2014101366A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018026441A1 (en) * 2016-08-01 2018-02-08 The Regents Of The University Of California Methods for preventing or treating fibrotic diseases
JP7534335B2 (ja) 2019-05-30 2024-08-14 ベクトン・ディキンソン・アンド・カンパニー 薬物送達デバイス用のカートリッジアダプタ
KR20230083169A (ko) 2021-12-02 2023-06-09 대주전자재료 주식회사 다공성 규소-탄소 복합체, 이의 제조방법 및 이를 포함하는 음극 활물질

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09291039A (ja) * 1995-12-26 1997-11-11 Suntory Ltd プロシアニジンを有効成分とする抗肥満剤
DK0815857T3 (da) * 1995-12-26 2005-01-24 Suntory Ltd Anti-adipöst middel indeholdende procyanidin som den aktive ingrediens
GB9906515D0 (en) * 1999-03-22 1999-05-19 Europ I Of Oncology Materials and methods relating to the effects oF P66 expression
WO2000078326A1 (en) * 1999-06-18 2000-12-28 Dry Creek Nutrition, Inc. Method and composition for preventing or treating adverse physiological effects associated with cardiac disease
KR100509119B1 (ko) 1999-07-16 2005-08-18 주식회사 엘지생활건강 프로시아니딘 올리고머를 유효성분으로 하는 약제
NZ528322A (en) * 2001-03-15 2005-03-24 Proteotech Inc Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases such as alzheimer's disease and parkinson's
EP1256335A1 (de) * 2001-05-10 2002-11-13 Cognis France S.A. Verwendung von oligomeren Procyanolidinen
CN1443533A (zh) * 2002-03-07 2003-09-24 程彦杰 原花青素类化合物在用于制备解酒保肝产品方面的用途
KR100531472B1 (ko) * 2002-08-09 2005-11-28 주식회사 이롬 항산화 활성을 가지는 찔레나무 추출물을 포함하는 화장품 조성물 및 상기 추출물의 제조방법
JP2006232670A (ja) * 2003-05-20 2006-09-07 Ajinomoto Co Inc 神経障害用薬剤
JP2005097273A (ja) * 2003-08-19 2005-04-14 Toyo Shinyaku:Kk 運動能力向上組成物
WO2005030200A1 (ja) * 2003-09-26 2005-04-07 Kirin Beer Kabushiki Kaisha 自己免疫疾患治療剤
GB2435166B (en) * 2004-11-04 2009-07-08 Univ Tsukuba High molecular weight polphenols extracted from fermented tea and a method of manufacturing a medicament for the prevention and treatment of diabetes
CN100586431C (zh) * 2007-09-28 2010-02-03 天津市尖峰天然产物研究开发有限公司 原花青素b2在制备防治糖尿病及血管并发症药物的应用
US20130123204A1 (en) * 2008-12-31 2013-05-16 Industrial Technology Research Institute Method for treating hepatitis b
TWI370736B (en) 2008-12-31 2012-08-21 Ind Tech Res Inst Pharmaceutical composition for treating hepatitis b and heath food for inhibiting hepatitis b virus
CN101822372A (zh) * 2009-03-05 2010-09-08 财团法人工业技术研究院 用以治疗b型肝炎的药学组合物与抑制b型肝炎病毒的保健食品
EA201190219A1 (ru) * 2009-04-17 2013-01-30 Кардеро Терапьютикс, Инк. Способы и композиции для лечения ишемических состояний и состояний, связанных с функцией митохондрий
TWI458487B (zh) 2009-12-30 2014-11-01 Ind Tech Res Inst 藥學組合物之用途
JP2011178728A (ja) 2010-03-02 2011-09-15 Kobe Univ Ａｍｐｋ活性化剤、ｇｌｕｔ４活性化剤、およびそれらを用いた医薬品・飲食品
WO2012126178A2 (zh) * 2011-03-22 2012-09-27 财团法人工业技术研究院 减缓肝癌恶化、改善肝功能、改善肝纤维化、改善肝硬化、改善肝发炎及促进受损肝脏再生之药物组合物
WO2012163588A2 (en) * 2011-05-27 2012-12-06 Unilever Plc Anti-ageing composition
CN103987704A (zh) * 2011-08-05 2014-08-13 卡德尔治疗公司 类黄酮化合物
JP5813576B2 (ja) * 2012-05-22 2015-11-17 アピオン・ジャパン有限会社 サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤
CN102688230B (zh) * 2012-06-20 2014-12-03 浙江萧山医院 原花青素b2的用途
CN102688501A (zh) * 2012-06-20 2012-09-26 浙江萧山医院 原花青素b2磷脂复合物及其制备方法和用途
US20150336981A1 (en) * 2012-11-08 2015-11-26 Cellarouge Pty Ltd Modified polyphenols and modified polyphenol compositions

Also Published As

Publication number Publication date
EP2838528A4 (en) 2015-09-09
EP2838528A1 (en) 2015-02-25
SG11201407425SA (en) 2014-12-30
EP2838528B1 (en) 2025-08-06
JP2016502532A (ja) 2016-01-28
KR20170027860A (ko) 2017-03-10
JP6305422B2 (ja) 2018-04-04
IN2014MN02382A (enExample) 2015-08-14
WO2014101366A1 (en) 2014-07-03
CN104487069A (zh) 2015-04-01
US20140179774A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
Han et al. Quercetin hinders microglial activation to alleviate neurotoxicity via the interplay between NLRP3 inflammasome and mitophagy
Liu et al. Ginseng protein protects against mitochondrial dysfunction and neurodegeneration by inducing mitochondrial unfolded protein response in Drosophila melanogaster PINK1 model of Parkinson's disease
Nieoczym et al. Effect of quercetin and rutin in some acute seizure models in mice
Rao et al. Downregulation of STIM2 improves neuronal survival after traumatic brain injury by alleviating calcium overload and mitochondrial dysfunction
He et al. Neuroprotective effects of osthole pretreatment against traumatic brain injury in rats
Elsherbiny et al. ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy
Hu et al. Ginkgolide B reduces neuronal cell apoptosis in the hemorrhagic rat brain: possible involvement of Toll-like receptor 4/nuclear factor-kappa B pathway
Zhao et al. Postischemic administration of liposome-encapsulated luteolin prevents against ischemia-reperfusion injury in a rat middle cerebral artery occlusion model
Huang et al. Tetramethylpyrazine attenuates lipopolysaccharide-induced cardiomyocyte injury via improving mitochondrial function mediated by 14-3-3γ
KR20150081422A (ko) mTOR 경로 관련 질병 치료를 위한 화합물
CN111714476B (zh) 胡黄连素二聚体类似物衍生物在制备防治帕金森病的药物中的应用
Wang et al. Effects of JIP3 on epileptic seizures: evidence from temporal lobe epilepsy patients, kainic-induced acute seizures and pentylenetetrazole-induced kindled seizures
KR20160068776A (ko) 방사선 효과의 완화 및 예방을 위한 조성물의 제조 및 용도
JP6305422B2 (ja) 老化関連疾患を克服するためにｓｈｃ−１／ｐ６６を抑制する方法
MX2011013311A (es) Propiedades neuroprotectoras de 5'-metiltioadenosina.
Zhou et al. Carvacrol acetate activated Nrf2 modulates mitophagy for the treatment of neurocyte oxidative stress induced by chlorpyrifos
US20160024135A1 (en) Adenosine receptor activation reagent and the uses of thereof
KR101637433B1 (ko) 알파-이소-쿠베베네를 유효성분으로 포함하는 신경 질환의 예방 또는 치료용 조성물
TWI484953B (zh) 聚合組合物在製備調控SHC-1/p66基因作用之藥物的用途
CN105712982B (zh) 二氢-β-沉香呋喃型倍半萜类化合物、其制法和用途
EP3257518A1 (en) A pharmaceutical composition for treating or alleviating autoimmune-related diseases and use of an acitive ingredient in the pharmaceutical composition
KR102208221B1 (ko) 신경근육질환의 예방 또는 치료용 약학적 조성물
KR20130005118A (ko) 사우치논을 유효성분으로 포함하는 근위축 억제 및 예방용 조성물
KR100529991B1 (ko) 간염 치료제 및 예방제 또는 간보호제로 유용한 섬오갈피추출물
KR102561140B1 (ko) 치매 예방 또는 치료용 약학 조성물

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20141127

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151211

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160729

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20151211

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20160729

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20160311

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20161129

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20161028

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20160729

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160311

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20151211

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170224